Irina Zharkikh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Irina Zharkikh has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Edgar Sergeevich Pan
Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia
3 shared publications - Mariia Zhukova
Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia
3 shared publications - Natalia Nicolaevna Ermakova
Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia
3 shared publications - Valentina Pan
Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia
3 shared publications - Victoria Skurikhina
Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia
3 shared publications - Alexander Dygai
Institute of General Pathology and Pathophysiology, Moscow 125315, Russia
2 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2330
Sympathetic Modulation of Neuroinflammation by Reserpine Improves Neurogenesis in ICR Mice with Traumatic Brain Injury
Background: Reserpine’s effect on sympathetic regulation of inflammatory cell mobilization and migration reduces neuroinflammation after traumatic brain injury (TBI). We hypothesize that an important consequence of reserpine effect may be the acceleration of brain regenerative processes. Methods: Neuroinflammation and the response of neuronal cells and neural stem cells in the cerebral cortex (CC) and subventricular zone (SVZ) of ICR mice after TBI and reserpine treatment were assessed using histological and immunohistochemical methods. Results: TBI was accompanied by neuroinflammation, cellular and tissue degeneration, neuronal cell damage, and impaired proliferation of neural stem cells in CC and SVZ. Reserpine administration inhibited neuroinflammation and reduced the severity of degenerative processes. Furthermore, an increase in the number of neural stem cells and neuronal cells was observed in the CC and SVZ. Conclusions: Reserpine is a promising compound for developing a new approach to TBI therapy aimed at blocking the sympathetic pathway of neuroinflammation and degeneration. This results in accelerated neuronal cell regeneration.
- 13 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2330
Open AccessSympathetic Modulation of Neuroinflammation by Reserpine Improves Neurogenesis in ICR Mice with Traumatic Brain Injury
Background: Reserpine’s effect on sympathetic regulation of inflammatory cell mobilization and migration reduces neuroinflammation after traumatic brain injury (TBI). We hypothesize that an important consequence of reserpine effect may be the acceleration of brain regenerative processes. Methods: Neuroinflammation and the response of neuronal cells and neural stem cells in the cerebral cortex (CC) and subventricular zone (SVZ) of ICR mice after TBI and reserpine treatment were assessed using histological and immunohistochemical methods. Results: TBI was accompanied by neuroinflammation, cellular and tissue degeneration, neuronal cell damage, and impaired proliferation of neural stem cells in CC and SVZ. Reserpine administration inhibited neuroinflammation and reduced the severity of degenerative processes. Furthermore, an increase in the number of neural stem cells and neuronal cells was observed in the CC and SVZ. Conclusions: Reserpine is a promising compound for developing a new approach to TBI therapy aimed at blocking the sympathetic pathway of neuroinflammation and degeneration. This results in accelerated neuronal cell regeneration.
- Open Access
- 13 December 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 3080
Sympathetic Regulation of Hematopoiesis and the Mobilization of Inflammatory Cells in ICR Mice with Traumatic Brain Injury: A Novel Approach to Targeting Neuroinflammation and Degenerative Processes
Background/Objectives: Neuroinflammation is a leading factor in secondary brain damage following a traumatic brain injury (TBI). Existing therapeutic approaches have limited efficacy against neuroinflammation. The bone marrow, the primary hematopoietic organ, is also a source of inflammatory cells. We propose that targeting the sympathetic regulation of inflammatory cell mobilization could reduce neuroinflammation after TBI. Methods: In ICR mice, we investigated the immune cell response in the blood, bone marrow, motor cortex, and the subventricular zone after TBI modeling and treatment with the sympatholytic agent reserpine. Results: TBI induced neutrophilia and lymphocytosis in the peripheral blood, activated hematopoiesis in the bone marrow, and triggered neuroinflammation and degenerative changes in the cerebral cortex (CC) and the subventricular zone (SVZ) of mice. Reserpine reduced leukocytosis in the blood and hematopoietic activity in the bone marrow of mice with TBI compared to untreated TBI mice. Furthermore, reserpine decreased neutrophilic and lymphocytic infiltration, as well as the number of Iba1+ microglial cells, including M1-polarized microglia, Caspase-3+ cells, and cells expressing myeloperoxidase (MPO) in the CC and SVZ of treated mice. The activity of degenerative processes was also reduced. Additionally, reserpine reduced the number of M2-polarized microglial cells in the SVZ. Conclusions: The sympatholytic drug reserpine may hold promise for the development of a novel approach to treating neuroinflammation and degeneration following a TBI. This is based on its ability to reduce hematopoiesis and mobilize inflammatory cells from the bone marrow into the bloodstream.
- 13 December 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 3080
Open AccessSympathetic Regulation of Hematopoiesis and the Mobilization of Inflammatory Cells in ICR Mice with Traumatic Brain Injury: A Novel Approach to Targeting Neuroinflammation and Degenerative Processes
Background/Objectives: Neuroinflammation is a leading factor in secondary brain damage following a traumatic brain injury (TBI). Existing therapeutic approaches have limited efficacy against neuroinflammation. The bone marrow, the primary hematopoietic organ, is also a source of inflammatory cells. We propose that targeting the sympathetic regulation of inflammatory cell mobilization could reduce neuroinflammation after TBI. Methods: In ICR mice, we investigated the immune cell response in the blood, bone marrow, motor cortex, and the subventricular zone after TBI modeling and treatment with the sympatholytic agent reserpine. Results: TBI induced neutrophilia and lymphocytosis in the peripheral blood, activated hematopoiesis in the bone marrow, and triggered neuroinflammation and degenerative changes in the cerebral cortex (CC) and the subventricular zone (SVZ) of mice. Reserpine reduced leukocytosis in the blood and hematopoietic activity in the bone marrow of mice with TBI compared to untreated TBI mice. Furthermore, reserpine decreased neutrophilic and lymphocytic infiltration, as well as the number of Iba1+ microglial cells, including M1-polarized microglia, Caspase-3+ cells, and cells expressing myeloperoxidase (MPO) in the CC and SVZ of treated mice. The activity of degenerative processes was also reduced. Additionally, reserpine reduced the number of M2-polarized microglial cells in the SVZ. Conclusions: The sympatholytic drug reserpine may hold promise for the development of a novel approach to treating neuroinflammation and degeneration following a TBI. This is based on its ability to reduce hematopoiesis and mobilize inflammatory cells from the bone marrow into the bloodstream.
- Open Access
- 9 December 2025
- Published by MDPI AG in Preprints.org
Sympathetic Regulation of Hematopoiesis and the Mobilization of Inflammatory Cells in ICR Mice with Traumatic Brain Injury: A Novel Approach to Targeting Neuroinflammation and Degenerative Processes
Background/Objectives: Neuroinflammation is a leading factor in secondary brain damage following a traumatic brain injury (TBI). Existing therapeutic approaches have limited efficacy against neuroinflammation. The bone marrow, the primary hematopoietic organ, is also a source of inflammatory cells. We propose that targeting the sympathetic regulation of inflammatory cell mobilization could reduce neuroinflammation after TBI. Methods: In ICR mice, we investigated the immune cell response in the blood, bone marrow, motor cortex, and the subventricular zone after TBI modeling and treatment with the sympatholytic agent reserpine. Results: TBI induced neutrophilia and lymphocytosis in the peripheral blood, activated hematopoiesis in the bone marrow, and triggered neuroinflammation and degenerative changes in the cerebral cortex (CC) and the subventricular zone (SVZ) of mice. Reserpine reduced leukocytosis in the blood and hematopoietic activity in the bone marrow of mice with TBI compared to untreated TBI mice. Furthermore, reserpine decreased neutrophilic and lymphocytic infiltration, as well as the number of Iba1+ microglial cells, including M1-polarized microglia, Caspase-3+ cells, and cells expressing myeloperoxidase (MPO) in the CC and SVZ of treated mice. The activity of degenerative processes was also reduced. Additionally, reserpine reduced the number of M2-polarized microglial cells in the SVZ. Conclusions: The sympatholytic drug reserpine may hold promise for the development of a novel approach to treating neuroinflammation and degeneration following a TBI. This is based on its ability to reduce hematopoiesis and mobilize inflammatory cells from the bone marrow into the bloodstream.
- 9 December 2025
- Published by MDPI AG in Preprints.org
Open AccessSympathetic Regulation of Hematopoiesis and the Mobilization of Inflammatory Cells in ICR Mice with Traumatic Brain Injury: A Novel Approach to Targeting Neuroinflammation and Degenerative Processes
Background/Objectives: Neuroinflammation is a leading factor in secondary brain damage following a traumatic brain injury (TBI). Existing therapeutic approaches have limited efficacy against neuroinflammation. The bone marrow, the primary hematopoietic organ, is also a source of inflammatory cells. We propose that targeting the sympathetic regulation of inflammatory cell mobilization could reduce neuroinflammation after TBI. Methods: In ICR mice, we investigated the immune cell response in the blood, bone marrow, motor cortex, and the subventricular zone after TBI modeling and treatment with the sympatholytic agent reserpine. Results: TBI induced neutrophilia and lymphocytosis in the peripheral blood, activated hematopoiesis in the bone marrow, and triggered neuroinflammation and degenerative changes in the cerebral cortex (CC) and the subventricular zone (SVZ) of mice. Reserpine reduced leukocytosis in the blood and hematopoietic activity in the bone marrow of mice with TBI compared to untreated TBI mice. Furthermore, reserpine decreased neutrophilic and lymphocytic infiltration, as well as the number of Iba1+ microglial cells, including M1-polarized microglia, Caspase-3+ cells, and cells expressing myeloperoxidase (MPO) in the CC and SVZ of treated mice. The activity of degenerative processes was also reduced. Additionally, reserpine reduced the number of M2-polarized microglial cells in the SVZ. Conclusions: The sympatholytic drug reserpine may hold promise for the development of a novel approach to treating neuroinflammation and degeneration following a TBI. This is based on its ability to reduce hematopoiesis and mobilize inflammatory cells from the bone marrow into the bloodstream.